Corcept Therapeutics Incorporated Announces FDA Approval of Korlym(TM) (Mifepristone): First and Only Approved Medication for Cushing's Syndrome Patients
February 17, 2012 18:16 ET
|
Corcept Therapeutics
MENLO PARK, CA--(Marketwire - Feb 17, 2012) - Corcept Therapeutics Incorporated (NASDAQ: CORT) announced today that the U.S. Food and Drug Administration (FDA) has approved Korlym™...
FDA Will Not Require a Risk Evaluation and Mitigation Strategy in Connection With Corcept's Proposed Distribution of Korlym(TM) for Cushing's Syndrome
December 15, 2011 09:00 ET
|
Corcept Therapeutics
MENLO PARK, CA--(Marketwire - Dec 15, 2011) - Corcept Therapeutics Incorporated (NASDAQ: CORT), a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the...
Corcept Therapeutics Announces Third Quarter Results and Corporate and Development Update
November 07, 2011 09:00 ET
|
Corcept Therapeutics
MENLO PARK, CA--(Marketwire - Nov 7, 2011) - Corcept Therapeutics Incorporated (NASDAQ: CORT), a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the...
Gary C. Robb Joins Corcept as Chief Financial Officer
August 22, 2011 09:00 ET
|
Corcept Therapeutics
MENLO PARK, CA--(Marketwire - Aug 22, 2011) - Corcept Therapeutics (NASDAQ: CORT) today announced the appointment of Gary C. ("Charlie") Robb to the position of Chief Financial Officer, effective...
No FDA Advisory Committee Meeting Planned in Connection With New Drug Application for CORLUX for Cushing's Syndrome
August 22, 2011 09:00 ET
|
Corcept Therapeutics
MENLO PARK, CA--(Marketwire - Aug 22, 2011) - Corcept Therapeutics Incorporated (NASDAQ: CORT), a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the...
Corcept Therapeutics Announces Second Quarter Results and Corporate and Development Update
August 08, 2011 08:00 ET
|
Corcept Therapeutics
MENLO PARK, CA--(Marketwire - Aug 8, 2011) - Corcept Therapeutics Incorporated (NASDAQ: CORT), a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the...
FDA Accepts Submission of New Drug Application for CORLUX for Cushing's Syndrome
June 30, 2011 08:00 ET
|
Corcept Therapeutics
MENLO PARK, CA--(Marketwire - Jun 30, 2011) - Corcept Therapeutics Incorporated (NASDAQ: CORT), a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the...
Corcept Therapeutics Announces Detailed Findings From Phase 3 Study Which Show CORLUX Significantly Improves Clinical and Metabolic Manifestations of Cushing's Syndrome
June 04, 2011 12:45 ET
|
Corcept Therapeutics
MENLO PARK, CA--(Marketwire - Jun 4, 2011) - Corcept Therapeutics Incorporated (NASDAQ: CORT), a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the...
Corcept Therapeutics Announces Conference Call to Discuss Detailed Findings From Corlux Phase 3 Trial in Cushing's Syndrome at the Endocrine Society's Annual Meeting
June 01, 2011 08:00 ET
|
Corcept Therapeutics
MENLO PARK, CA--(Marketwire - Jun 1, 2011) - Corcept Therapeutics Incorporated (NASDAQ: CORT), a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the...
Corcept Therapeutics to Present Detailed Findings From CORLUX Phase 3 Trial in Cushing's Syndrome at the Endocrine Society's Annual Meeting, June 4-7
May 19, 2011 08:00 ET
|
Corcept Therapeutics
MENLO PARK, CA--(Marketwire - May 19, 2011) - Corcept Therapeutics Incorporated (NASDAQ: CORT), a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the...